Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s National Energy Development Organization To Start Large-Scale Alzheimer’s Disease Trial

This article was originally published in PharmAsia News

Executive Summary

To detect early signs of Alzheimer's disease in Japanese people and contribute to new drug development, Japan's National Energy Development Organization announced April 19 a plan to start a large scale trial in 36 facilities nationwide. The center plans to recruit 600 early stage patients and conduct various diagnostics in a 2-3 year period. Ten major Japanese drug companies including Astellas and seven device makers including GE Yokokawa Medical System also agreed to collaborate. NEDO plans to utilize magnetic resonance imaging and positron emission tomography technologies to measure brain size and memory loss. It will be the first such trial in Japan. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts